Last updated on February 2020

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

Brief description of study

This is an open-label, multicenter, phase I study to evaluate the safety and tolerability of durvalumab tremelimumab in combination with chemoradiation in patients with advanced solid tumors

Detailed Study Description

This study will initially treat up to approximately 300 patients with advanced solid tumors at approximately 30 sites, worldwide. The study will be composed of a dose-limiting toxicity (DLT) assessment phase (Part A) and an expansion phase (Part B).

Clinical Study Identifier: NCT03509012

Find a site near you

Start Over

Research Site

Koto-ku, Japan
  Connect »